EU panel backs Revolution Medicines' pancreatic cancer drug
Europe's drug regulator panel recommended approving Revolution Medicines (RVMD) and its drug Rasonque for advanced pancreatic cancer, a cancer with few options once standard treatment fails. It follows August's US clearance. Stanley Druckenmiller holds a long stake. Final EU sign-off still rests with the European Commission.
Sources
EMA Panel Recommends EU Approval of Revolution Medicines' Rasonque for Advanced Pancreatic Cancer After August US Clearance
The whole story · updated
R
Reuters
·
EMA panel backs approval of Revolution's pancreatic cancer drug